These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26433553)

  • 1. The Master Protocol Concept.
    Redman MW; Allegra CJ
    Semin Oncol; 2015 Oct; 42(5):724-30. PubMed ID: 26433553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
    Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
    Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K; O'Sullivan Coyne G; Chen AP
    Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung cancer as a paradigm for precision oncology in solid tumours.
    Schallenberg S; Merkelbach-Bruse S; Buettner R
    Virchows Arch; 2017 Aug; 471(2):221-233. PubMed ID: 28730537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.
    Hyman DM; Solit DB; Arcila ME; Cheng DT; Sabbatini P; Baselga J; Berger MF; Ladanyi M
    Drug Discov Today; 2015 Dec; 20(12):1422-8. PubMed ID: 26320725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine.
    Damodaran S; Berger MF; Roychowdhury S
    Am Soc Clin Oncol Educ Book; 2015; ():e175-82. PubMed ID: 25993170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 9. Perspective on Precision Medicine in Oncology.
    Johnson TM
    Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy: a potential oversight in trial protocol.
    Moorthy T
    Lancet Oncol; 2018 Sep; 19(9):e439. PubMed ID: 30191846
    [No Abstract]   [Full Text] [Related]  

  • 11. Pediatric oncology enters an era of precision medicine.
    Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
    Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine: In need of guidance and surveillance.
    Lin JZ; Long JY; Wang AQ; Zheng Y; Zhao HT
    World J Gastroenterol; 2017 Jul; 23(28):5045-5050. PubMed ID: 28811702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
    Lih CJ; Takebe N
    Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating genomics for precision cancer medicine.
    Roychowdhury S; Chinnaiyan AM
    Annu Rev Genomics Hum Genet; 2014; 15():395-415. PubMed ID: 25184532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
    Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
    Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic medicine and risk prediction across the disease spectrum.
    Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW
    Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer genomics guide clinical practice in personalized medicine.
    Lehmann-Che J; Poirot B; Boyer JC; Evrard A
    Therapie; 2017 Sep; 72(4):439-451. PubMed ID: 28258721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.
    Patterson SE; Liu R; Statz CM; Durkin D; Lakshminarayana A; Mockus SM
    Hum Genomics; 2016 Jan; 10():4. PubMed ID: 26772741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic Mutation Analysis of Human Cancers: Challenges in Clinical Practice.
    Tsongalis GJ; Coleman WB
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S60-S66. PubMed ID: 28921651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.